Rangaswamy Chintapatla, MD
Medical Oncology · Kennewick, WANPI 1003131640
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,562 of the $49,825 with a category attached, or 75.4%. It is spread thinly across 21 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2022 at $17,594 and has fallen 74.4% since, to $4,505 in 2025.
Across 104 payments — averaging $479.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- AstraZeneca$10K
- Gilead$5K
- E.r. Squibb & Sons, L.L.C.$5K
- Johnson & Johnson$4K
- Bristol Myers Squibb$3K
- plus $12K from 15 others
Across 232 payments — averaging $5736.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$553K
- Seagen Inc.$249K
- Merck$204K
- Otsuka Pharmaceutical Co., Ltd.$124K
- AstraZeneca$45K
- Incyte Corporation$43K
- plus $113K from 5 others
What the payments were for
- Consulting fees$37,56275%
- Speaking & faculty fees$4,1508%
- Travel & lodging$6,06912%
- Food & beverage$1,8734%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $11,318 |
| AstraZeneca | 15 | $9,517 |
| Gilead(2 entities) | 11 | $5,270 |
| E.r. Squibb & Sons, L.L.C. | 9 | $5,154 |
| Johnson & Johnson | 12 | $3,588 |
| Bristol Myers Squibb | 6 | $3,421 |
| GSK | 3 | $2,532 |
| Array Biopharma Inc | 1 | $2,400 |
| Pfizer | 8 | $1,855 |
| Morphosys, US Inc. | 1 | $1,455 |
| Daiichi Sankyo Inc. | 1 | $1,410 |
| Incyte Corporation | 1 | $1,100 |
| Beigene, Ltd. | 1 | $450 |
| Novartis | 4 | $171 |
| Merck | 3 | $55 |
| Genentech USA, Inc. | 2 | $34 |
| Novocure Inc. | 1 | $31 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $17 |
| Seagen Inc. | 1 | $14 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,825 in reported general payments places this provider in the 85th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 65 | $866,480 |
| CabometyxCabozantinib S-Malate | 23 | $557,959 |
| BrukinsaZanubrutinib | 25 | $328,740 |
| XtandiEnzalutamide | 20 | $269,653 |
| IbrancePalbociclib | 16 | $248,183 |
| ImbruvicaIbrutinib | 20 | $229,770 |
| KisqaliRibociclib Succinate | 14 | $183,445 |
| LorbrenaLorlatinib | 12 | $176,374 |
| VenclextaVenetoclax | 16 | $160,744 |
| Abiraterone Acetate | 38 | $150,296 |
| EliquisApixaban | 45 | $29,637 |
| XareltoRivaroxaban | 19 | $20,218 |
| Imatinib Mesylate | 12 | $10,920 |
| Letrozole | 173 | $4,063 |
| Exemestane | 25 | $3,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Lorbrena, Eliquis | $1,855 | $454,19473 claims |
| NovartisKisqali | $171 | $183,44514 claims |
| AbbVieVenclexta | $11,318 | $160,74416 claims |
| Johnson & JohnsonXarelto | $3,588 | $20,21819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Kennewick
- Hakan KayaSpokane$2.2M
- Bart ScottSeattle$1.3M
- William BensingerLakewood$1.2M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Joseph YeOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.